EMA Says Novo Nordisk Informed For Ozempic, Intermittent Shortages Are Expected Throughout 2024
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency (EMA) has announced that Novo Nordisk has informed them of expected intermittent shortages of Ozempic throughout 2024. Ozempic, which contains the active substance semaglutide, is anticipated to be in short supply due to increased global demand.
November 21, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novo Nordisk is expected to face intermittent shortages of its diabetes medication Ozempic throughout 2024, as informed to the EMA.
The announcement of shortages for a key product like Ozempic could negatively impact Novo Nordisk's sales and investor sentiment in the short term. While the company may be able to mitigate some of the impact through supply chain adjustments, the news is likely to concern investors and could lead to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100